Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

Molecular Cell - United States
doi 10.1016/j.molcel.2012.06.014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Telomerase Inhibitor Imetelstat Alone, and in Combination With Trastuzumab, Decreases the Cancer Stem Cell Population and Self-Renewal of HER2+ Breast Cancer Cells

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

Expression of T-Darpp Mediates Trastuzumab Resistance in Breast Cancer Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Trastuzumab-Resistance and Breast Cancer

2011English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Doxorubicin Resistance Induces IL6 Activation in the Colon Cancer Cell Line LS180

Oncology Letters
Cancer ResearchOncology
2018English

ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Physical Intimacy of Breast Cancer Cells With Mesenchymal Stem Cells Elicits Trastuzumab Resistance Through SRC Activation

Scientific Reports
Multidisciplinary
2015English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy